PSA-GM Deal: Initial Thoughts

If finalised, a mooted deal for France's PSA Group to acquire the European Opel and Vauxhall division of General Motors Company (GM) would create the second-largest autos group in Europe by market share. Here we give our initial thoughts on the...

Read More

Bullish Break Signals Appreciation Ahead

With the rand pushing through several key levels of resistance in recent weeks, at ZAR13.20/USD and ZAR13.00/USD, we now anticipate continued, if unsteady gains over the coming quarters.

Read More

Revenue Diversification To Justify Vodafone's FTTH Investment

As rivals are already deploying fibre, Vodafone's FTTH initiative will not fundamentally alter Ghana's broadband competitive landscape. However, it will help the company's revenue-diversification strategy as well as dilute the threat posed by MTN's...

Read More

Kim Jong Nam's Death To Increase Regime Stresses

The assassination of Kim Jong Nam will raise stresses within the North Korean regime, as senior officials increasingly fear for their own wellbeing. No changes to foreign policy are likely, but the growing climate of fear is likely to increase the...

Read More

Tourism And High Incomes Driving Investment In Luxury

Bahrain is one of our favourite luxury goods markets in the Middle East, with the segment set for strong growth on the back of high household incomes and a growing reputation as a retail tourism destination. The development of modern retail spaces...

Read More

AT&T: Doubling Down On Convergence With Time Warner

AT&T is doubling down on its convergence and content strategy with its acquisition of Time Warner (pending approval) and the launch of its streaming service DirecTV NOW. The aim is to be able to offer premium and exclusive content to its...

Read More

Myriad Challenges Create An Uncertain Future For Teva

The acquisition of the Actavis Generics continues to have a pronounced impact on Teva Pharmaceutical Industries' financial performance. Teva has returned to be a primarily generics-led company; its generics segment sales for Q416 and the full-year...

Read More




By submitting this form you are acknowledging that you have read and understood our Privacy Policy.

Thank you for your interest

A member of the team will be in touch shortly to arrange a convenient time for your free demonstration and trial. If your enquiry is urgent, please email our Client Services team here.